Intermittent hormone therapy in nonmetastatic prostate cancer

Clinical Genitourinary Cancer

Volumn 5, Issue 2, 2006, Pages 138-143

  Opfermann, Krisha J ^a   Lai, Zongshan ^a   Essenmacher, Lynette ^a   Bolton, Sue ^a   Ager, Joel ^a   Forman, Jeffrey D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen resistance; Intermittent androgen deprivation; Prostate specific antigen; Testosterone

Indexed keywords

ANTIANDROGEN; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; DRUG POTENTIATION; HUMAN; MALE; MIDDLE AGED; PROSTATE TUMOR; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 39049181497     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2006.n.030     Document Type: Article

References (44)

1. Labrie F. Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease. Mol Cell Endocrinol 2002; 198:77-87.
2. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591-1597.
3. Grossfeld GD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 1998; 51:137-144.
4. Huggins C., Hodges CV. Studies of prostate cancer: the effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol 2002; 168:9-12.
5. Hurtado-Coll A., Goldenberg SL, Gleave ME, et al. Intermittent androgen suppression in prostate cancer: the Canadian experience. Urology 2002; 60:52-56.
6. Crawford ED, Eisenberger MA, McLeod DG. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321:419-424.
7. Denis LJ, Whelan P., De Moura C., et al. Goserelin acetate and flutamide versus bilateral orchidectomy: a phase III EORTC trial (30853). Urology 1993; 42:119-130.
8. Mottet N. Hormonal treatment alone for locally advanced prostate cancer. BJU Int 2004; 94:14-15.
9. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer 2000; 88:3009-3014.
10. Gingrich JR, Barrios RJ, Kattan M. W., et al. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997; 57:4687-4691.
11. Noble RL. Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Res 1977; 37:82-94.
12. Bruchovsky N., Rennie PS, Coldman AJ, et al. Effects of androgen withdrawal on the stem cell composition of the shionogi carcinoma. Cancer Res 1990; 50:2275-2282.
13. Akadura K., Bruchovsky N., Goldenberg SL, et al. Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate-specific antigen. Cancer 1993; 71:2782-2790.
14. Higano CS, Ellis W., Russell K., et al. Intermittent androgen suppression with leupro-lide and flutamide for prostate cancer: a pilot study. Urology 1996; 48:800-804.
15. Akakura K., Bruchovsky N., Rennie PS, et al. Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma. J Steroid Biochem Mol Biol 1996; 59:501-511.
16. Goldenberg L., Bruchovsky N., Gleave ME, et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995; 45:839-845.
17. de la Taille A., Vacherot F., Salomon, L., et al. Hormone-refractory prostate cancer: a multi-step and multi-event process. Prostate Cancer and Prostatic Dis 2001; 4:204-212.
18. Hockenbery DM, Zutter M., Hickey W., et al. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A 1991; 88:6961-6965.
19. Colombel M., Radvanyi F., Blanche M., et al. Androgen suppressed apoptosis is modified in p53 deficient mice. Oncogene 1995; 10:1269-1274.
20. Cardillo M., Berchem G., Tarkington MA, et al. Resistance to apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation. J Urol 1997; 158:212-216.
21. Bentel JM, Tilley WD. Androgen receptors in prostate cancer. J Endocrinol 1996; 151:1-11.
22. Wilding G. Endocrine control of prostate cancer. Cancer Surv 1995; 23:43-62.
23. Culig Z., Hobisch A., Hittmair A., et al. Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells. Prostate 1997; 32:106-114.
24. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. New Engl J Med 1995; 332:1393-1398.
25. Shen R., Dorai T., Szaboles M., et al. Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium. Urol Oncol 1997; 3:67-75.
26. Heidenberg HB, Bauer JJ, McLeod DG, et al. The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? Urology 1996; 48:971-979.
27. Yang G., Stapleton AM, Wheeler TM, et al. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res 1996; 2:399-401.
28. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. New Engl J Med 1993; 329:1318-1327.
29. Gkonos PJ, Krongrad A., Roos BA. Neuroendocrine peptides in the prostate. Urol Res 1995; 23:81-87.
30. Bonkhoff H., Wemert N., Dhom G., et al. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 1991; 19:91-98.
31. Isaacs JT, Coffey DS. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 1981; 41:5070-5075.
32. Isaacs J. T. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999; 26:263-273.
33. Gregory CW, He B., Johnson RT, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61:4315-4319.
34. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocrine Reviews 2004; 25:276-308.
35. Strum SB, Scholz MC, McDermed JE. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. The Oncologist 2000; 5:45-52.
36. Albrecht W., Collette L., Fava C., et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. Eur Urol 2003; 44:505-511.
37. de Leval J., Boca P., Yousef E., et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naïve prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002; 1:163-171.
38. de la Taille A., Zerbib M., Conquy S., et al. Predictive factors of biochemical progression in prostate cancer patients treated with intermittent androgen suppression. Eur Urol Supplements 2002; 1:S135.
39. de la Taille A., Zerbib M., Conquy S., et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int 2003; 9:18-20.
40. Youssef E., Tekyi-Mensah S., Hart K., et al. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer. Am J Clin Oncol 2003; 26:e119-e123.
41. Sato N., Akakura K., Shigeo I., et al. Prostate study group. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 2004; 64:341-345.
42. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157:439-444.
43. Townsend M. F., Sanders WH, Northway RO, et al. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997; 79:545-550.
44. Carroll PR, Kantoff P. W., Balk S. P., et al. Overview consensus statement. Urology 2002; 60:1-6.